Abstract
<p><span lang="EN-US">Biosimilar has the advantages of precise efficacy, high safety and stable quality, and occupy an important position in the field of anti-tumor therapy. In order to reduce the expenditure of drugs, the research and development of biosimilar drugs has attracted much attention. Compared with European and American countries in the development of the anti-tumor biosimilar industry, there are still some shortcomings and parts that need improvement in China. According to the current development status of China, analyzed the reasons for the development dilemma of my country’s anti-tumor biosimilar industry, and put forward suggestions for the development of this industry.</span></p>
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
